Topic: treatment-resistant tumors
Cancer has always mirrored evolution, but now researchers are developing a new class of drug that blocks the mutations that lead to drug resistance.
The mezzanine round will fund ORIC's lead asset through phase 1b and into phase 2 and move a second program into the clinic.
The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors.
Deciphera aims to get ripretinib approved first as a fourth- and second-line treatment for GIST, but is not looking for a first-line approval.
A phosphor-binding site on aberrantly spliced BRAF V600E could become a new target against drug-resistant melanoma.
TP Therapeutics and Almac will collaborate on a pan-cancer companion diagnostic for TP’s repotrectinib aimed at drug-resistant tumors.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
TP Therapeutics has the funds on hand to take its drug for resistant cancer through the next stages of clinical development after raising $45 million in a series C financing.
Kitov Pharmaceuticals has bought a 56% stake in TyrNovo to take control of a cancer program.